PART II - The 1st FDA approved oral testosterone: Meet Kyzatrex®

madman

Super Moderator
* 22:35 Why Kyzatrex Is Cash-Pay

* 07:10 Real-World Kyzatrex Results





Founder, CEO, and visionary behind Marius Pharmaceuticals, the company that brought Kyzatrex to market—the first FDA-approved oral testosterone replacement therapy. With a background in private equity and investing, he moved into biotech to solve a long-standing problem in hormone health: making testosterone therapy more accessible, more practical, and aligned with modern lifestyles—while supporting education, stigma reduction, and better men’s health outcomes.

In this two-part roundtable, the Biohacking Brothers sit down with Shalin Shah to break down why testosterone is a foundational longevity hormone, how Kyzatrex became the first FDA-approved oral testosterone, and what makes oral pulsatile dosing different from traditional injections. They cover cardiovascular and cognitive implications, stigma and access, fertility concerns, SHBG and free testosterone, estrogen myths, safety markers like hematocrit, and why patient education and proper lab interpretation matter—especially in a world where testosterone levels are declining across younger men.




Chapters


00:00 Why Pulsatile Testosterone Matters
02:25 Oral Testosterone and Accessibility
03:00 Fertility and Testosterone Therapy
05:35 Hematocrit and Cardiovascular Risk
06:05 SHBG and Free Testosterone
07:10 Real-World Kyzatrex Results
09:30 Why Total Testosterone Misleads
15:10 Estrogen Myths in TRT
18:45 GLP-1 Drugs and Muscle Loss
22:35 Why Kyzatrex Is Cash-Pay
26:20 Descheduling Testosterone
28:10 The Future of Hormone Optimization
 
 

ExcelMale Newsletter Signup

Online statistics

Members online
1
Guests online
371
Total visitors
372

Latest posts

Beyond Testosterone Podcast

Back
Top